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Background: Kidneys	 from	deceased	donors	 infected	with	hepatitis	C	virus	 (HCV)	
are	underutilized.	Most	HCV	virus-infected	donors	are	designated	as	Public	Health	
Service	increased	donors	(PHS-IR).	Impact	of	PHS	and	HCV	designations	on	discard	
is not well studied.
Methods: We	queried	the	UNOS	data	set	for	all	deceased	donor	kidneys	between	
January	2015	and	December	2018.	The	final	study	cohort	donors	(n	=	38	702)	were	
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1  | INTRODUC TION
Renal	transplantation	(RT)	is	the	treatment	of	choice	for	end-stage	
renal	 disease	 (ESRD).1,2 Despite recent increases in the number 
of	deceased	donor	 (DD)	RT,3	 there	still	exists	a	wide	gap	between	
supply	 and	 demand	 for	 RT.	While	 there	 has	 been	 a	 concerted	 ef-
fort	 to	 maximize	 the	 utilization	 of	 kidneys	 from	 existing	 donors4 
and	to	increase	the	donor	pool	as	well,5	the	proportion	of	kidneys	
discarded	 remains	high.	The	 last	decade	 in	 the	United	States	 (US)	
has	witnessed	 a	 significant	 change	 in	 the	 demographics	 of	 opioid	
users.6	Opioid	use	is	increasing	among	Caucasians	with	even	higher	
rates	in	the	Midwestern	United	States.	Heroin	use	went	up	fivefold	

















The	purpose	of	 our	 study	was	 to	 analyze	 the	 trends	 in	 center	
specific,	organ	procurement	organization	 (OPO)	 level,	 regional	uti-
lization	of	 adult	 kidney	donors	 based	on	donor	HCV	Ab	 and	NAT	
status,	 study	 the	 impact	 of	PHS	 labeling	 and	HCV	designation	on	
discard	of	those	kidneys,	and	forecast	the	number	of	HCV	viremic	
donors by 2023.
2  | PATIENTS AND METHODS/MATERIAL S 
AND METHODS
2.1 | Study population
This	 study	 used	 data	 from	 the	OPTN	 STAR	 files	 administered	 by	
the	United	Network	of	Organ	Sharing	(UNOS),	which	includes	data	
submitted	 by	 members	 on	 all	 donors,	 waitlisted	 candidates,	 and	
transplant	recipients	in	the	United	States.	The	Health	Resources	and	
Services	Administration	(HRSA)	of	the	US	Department	of	Health	and	
Human	Services	 (DHHS)	 oversees	 the	 activities	 of	 the	OPTN	and	
the	contractor.	The	University	of	Texas	Southwestern	 Institutional	
Review Board approved the study.




deceased	donors	 as	 a	 final	 cohort	 during	 the	 study	period.	 For	
our	analyses,	HCV	uninfected	donor	 is	defined	as	a	donor	with	
negative	HCV	Ab	 and	 negative	NAT	 (HCV	Ab−/NAT−);	 an	HCV	
seropositive,	non-viremic	donor	 is	defined	as	a	donor	with	pos-
itive	HCV	Ab	and	negative	NAT	 (HCV	Ab+/NAT−);	 and	 an	HCV	
viremic	donor	 is	 identified	as	a	subject	with	positive	HCV	NAT,	
regardless	 of	 the	 HCV	 Ab	 status	 (HCV	 Ab	 ±/NAT+).	 The	 term	
“HCV-positive	 donor”	 refers	 to	 donors	with	 a	 positive	HCV	Ab	
and/or	positive	HCV	NAT.
The	 study	 cohort	 donors	 (n	 =	 38	 702)	 were	 stratified	 into	
three	 groups	 based	 on	HCV	Ab	 and	NAT	 status:	 (a)	 Ab−/NAT−	
(n	=	35	861);	(b)	Ab+/NAT−	(n	=	973),	and	(c)	Ab±/NAT+	(n	=	1868).	
Under	each	HCV	categories,	the	kidneys	(N	=	70	450)	from	above	
donors	were	 further	 classified	 as	 “PHS-IR”	 or	 “PHS-IR”	 for	 the	
logistic	regression	analysis	to	predict	discard:	(a)	HCV	Ab−/NAT−	
(n	 =	 66	 224)	 category	 was	 composed	 of	 PHS-IR	 (n	 =	 13	 411,	
20.3%)	 and	 PHS-IR	 (n	 =	 52	 787,	 79.7%);	 (b)	 HCV	 Ab+/NAT−	
(n	=	1459)	category	was	composed	of	PHS-IR	(n	=	1030,	70.7%)	
and	PHS-IR	(n	=	427,	29.3%);	(c)	HCV	Ab±/NAT+	(n	=	2767)	cat-



















cally	 significant.	 Statistical	 analyses	were	 performed	with	 Stata/
MP14	 (StataCorp	 LP)	 and	 R	 Free	 Software	 Foundation	 (version	
3.5.1	version).
To	 account	 for	 variations	 in	 discard	 rates	 among	 the	 UNOS	
Regions	(there	are	total	of	11	regions	in	the	US)	and	OPOs	(there	
are	 total	 of	 58	OPOs	 under	 eleven	UNOS	 Regions),	 we	 utilized	
multilevel	(two-level	and	three-level	models)	mixed-effect	logistic	
regression	models.	For	this	analysis,	we	used	the	Stata	command	
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of	“melogit”	which	fits	mixed-effects	models	for	binary	responses	
(https	://www.stata.com/manua	ls14/melog	it.pdf).	 Mixed-effects	
logistic	 regression	 contains	 both	 fixed	 and	 random	effects.	 It	 is	
useful	for	modeling	intracluster	correlation	because	donors	in	the	
same	cluster	(the	UNOS	Region	or	OPO)	are	correlated	and	share	
common	 cluster-level	 random	 effects.	 We	 run	 three	 separate	
mixed-effects	logistic	regression	analysis	defining	random	effects	
for	(a)	the	UNOS	Regions	(two-level	models);	(b)	OPOs	(two-level	
models);	 and	 (c)	OPOs	nested	within	 the	UNOS	Regions	 (three-
level	 models).	 For	 simplicity,	 we	 only	 reported	 results	 of	 the	
mixed-effects	 logistic	 regression	models	 for	 the	UNOS	 Regions	
(two-level	models)	because	 the	 results	of	other	 two	models	 (for	
OPOs	and	OPOs	nested	within	the	UNOS	Regions)	did	not	show	
any	major	differences.
The	 mixed-effects	 logistic	 regression	 models	 were	 adjusted	
for	 previously	 identified	 donor	 factors	 in	 the	 literature,25,26 













itivity	 is	 forecasted	 into	 the	 year	 2023	 using	 time	 series	 analysis	
with	trend	adjusted	exponential	smoothing	method;	Excel's	built-in	
FORECAST.ETS	function	was	utilized	for	this	purpose.
F I G U R E  1  Flowchart	of	deceased	donors	registered	in	the	UNOS	database	between	January	1,	2015,	and	December	31,	2018,	in	the	
United	States
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TA B L E  2  Characteristics	of	transplanted	deceased	donor	kidneys	by	HCV	status	between	January	1,	2015,	and	December	31,	2018,	in	
the	United	States
 All groups Ab−, NAT− Ab+, NAT− Ab±, NAT+ All ways
 P-valuesa  
Ab−, NAT− vs. Ab+, NAT− vs.
Ab+, NAT− Ab±, NAT+ Ab±, NAT+
nb 56	833 54 232 968 1633     
Age	(y),	Mean	±	SD 36.3	±	15.9 36.3	±	16.2 37.2	±	10.8 32.9	±	8.4 <.001	*** .163 <.001	*** <.001	***
Gender,	n	(%)     <.001	*** <.001	*** .199 <.001	***
Female 21	664	(38.1) 20	617	(38.0) 462	(47.7) 585	(35.8)     
Male 35	169	(61.9) 33	615	(62.0) 506	(52.3) 1048	(64.2)     
Race,	n	(%)     <.001	*** <.001	*** <.001	*** .470
White 38	147	(67.1) 35	927	(66.2) 842	(87.0) 1378	(84.4)     
Black 8020	(14.1) 7910	(14.6) 34	(3.5) 76	(4.7)     
Hispanic 8148	(14.3) 7930	(14.6) 68	(7.0) 150	(9.2)     
Other 2518	(4.4) 2465	(4.5) 24	(2.5) 29	(1.8)     
BMI	(kg/m2),	
Mean	±	SD
27.5	±	7.1 27.6	±	7.1 28.1	±	6.3 26.1	±	5.1 <.001	*** <.001	*** <.001	*** <.001	***
Blood	type,	n	(%)     <.001	*** .010	** .005	** .919
O 27	269	(48.0) 25	915	(47.8) 503	(52.0) 851	(52.1)     
A 21	079	(37.1) 20	184	(37.2) 347	(35.8) 548	(33.6)     
B 6629	(11.7) 6308	(11.6) 105	(10.8) 216	(13.2)     
AB 1856	(3.3) 1825	(3.4) 13	(1.3) 18	(1.1)     
DCD,	n	(%)     <.001	*** <.001	*** <.001	*** .207
No 45	931	(80.8) 43	590	(80.4) 854	(88.2) 1487	(91.1)     
Yes 10	902	(19.2) 10	642	(19.6) 114	(11.8) 146	(8.9)     
ECD,	n	(%)     <.001	*** <.001	*** <.001	*** .001	**
No 49	968	(87.9) 47	446	(87.5) 909	(93.9) 1613	(98.8)     
Yes 6865	(12.1) 6786	(12.5) 59	(6.1) 20	(1.2)     
Diabetes	(any	type),	
n	(%)
    <.001	*** .431 <.001	*** <.001	***
No 52	910	(93.6) 50	398	(93.5) 909	(94.5) 1603	(98.8)     
Yes 3600	(6.4) 3527	(6.5) 53	(5.5) 20	(1.2)     
Hypertension,	n	(%)     <.001	*** .441 <.001	*** <.001	***
No 42	259	(74.9) 40	073	(74.4) 731	(76.2) 1455	(90.0)     
Yes 14	166	(25.1) 13	776	(25.6) 228	(23.8) 162	(10.0)     
PHS	increased	risk,	
n	(%)
    <.001	*** <.001	*** <.001	*** <.001	***
No 43	016	(75.7) 42	554	(78.5) 243	(25.1) 219	(13.4)     
Yes 13	809	(24.3) 11	670	(21.5) 725	(74.9) 1414	(86.6)     
Cause	of	death,	n	(%)     <.001	*** <.001	*** <.001	*** .490
Anoxia 23	267	(40.9) 21	417	(39.5) 691	(71.4) 1159	(71.0)     
Cerebrovascular 12	864	(22.6) 12	622	(23.3) 113	(11.7) 129	(7.9)     
Head	Trauma 18	908	(33.3) 18	446	(34.0) 147	(15.2) 315	(19.3)     
Other 1794	(3.2) 1747	(3.2) 17	(1.8) 30	(1.8)     








     |  7 of 16ARIYAMUTHU eT Al.
3  | RESULTS
3.1 | The study cohort selection




the	 71	 084	 kidneys	 that	 were	 procured,	 56	 833	 (73.9%)	 kidneys	
were	transplanted,	13	617	(17.7%)	kidneys	were	discarded,	and	634	
(0.8%)	were	used	for	research.
3.2 | Characteristics of all deceased donors by HCV 
status and disposition












less	 donation	 after	 circulatory	 death	 (DCD)	 donors.	 As	 expected,	
HCV	viremic	donors	also	had	higher	KDPI	and	were	also	more	likely	
to	be	labeled	as	PHS	-	IR	donors.
3.3 | Disposition of deceased donor kidneys by 
HCV status
Trends	 in	 deceased	 donor	 kidney	 disposition	 by	HCV	 status	 over	
time	is	shown	in	Figure	2.	Number	of	Ab+/NAT−	kidneys	that	were	
transplanted	increased	from	103	(35.9%	of	such	kidneys)	in	2015	to	
444	 (66%)	 in	2018.	The	discard	 rate	 in	 the	same	group	decreased	
from	 32.4%	 to	 22.4%.	 The	 percentage	 of	 viremic	 donor	 kidneys	
transplanted	 (from	41%	to	50%)	and	discarded	 (from	32%	to	33%)	
slightly	increased.	Disposition	categories	for	the	reference	group	re-
mained stable during the study period.
3.4 | Comparison of KDPI categories in 








median	KDPI	 percentage	was	 persistently	 higher	 in	 the	 discarded	
group during the study period.
3.5 | Reasons for kidney discard by HCV status
Table	4	 shows	 the	 reasons	 for	 kidney	discard	by	HCV	 status.	 ‘No	
recipient	 located/list	exhausted’	and	biopsy	findings	uniformly	ap-
pear	to	be	two	most	common	reasons	for	discard	across	all	groups.























reference	 group	 (PHS-IR	 in	 this	 category),	 HCV	Ab+/NAT−	 status	
increased	 the	 odds	 of	 discard	 by	 approximately	 2-fold	 (OR	 2.07,	
95%	 CI	 1.78-2.40)	 compared	 to	 the	 reference	 group	 (HCV	 Ab−/
NAT−	group).
In	HCV	Ab±/NAT+	group	(n	=	2767),	83.0%	of	the	kidneys	were	









PHS-IR,	 more	 recovery	 biopsies	 were	 performed	 (slightly	 higher	
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TA B L E  3  Characteristics	of	discarded	deceased	donor	kidneys	by	HCV	status	between	January	1,	2015,	and	December	31,	2018,	in	the	
United	States
 All groups Ab−, NAT− Ab+, NAT− Ab±, NAT+ All ways
 P-valuesa  
Ab−, NAT− vs. Ab+, NAT− vs.
Ab−, NAT− vs. 
Ab±, NAT+
Ab+, NAT− Ab±, NAT+  
nb 13	617 11 992 491 1134     
Age	(y),	Mean	±	SD 50.5	±	16.0 51.9	±	16.0 43.8	±	12.9 38.6	±	11.1 <.001	*** <.001	*** <.001	*** <.001	***
Gender,	n	(%)     <.001	*** .328 <.001	*** <.001	***
Female 6208	(45.6) 5573	(46.5) 245	(49.9) 390	(34.4)     
Male 7409	(54.4) 6419	(53.5) 246	(50.1) 744	(65.6)     
Race,	n	(%)     <.001	*** <.001	*** <.001	*** .832
White 9108	(66.9) 7786	(64.9) 394	(80.2) 928	(81.8)     
Black 2350	(17.3) 2221	(18.5) 40	(8.1) 89	(7.8)     
Hispanic 1565	(11.5) 1427	(11.9) 49	(10.0) 89	(7.8)     
Other 594	(4.4) 558	(4.7) 8	(1.6) 28	(2.5)     
BMI	(kg/m2),	Mean	±	SD 29.4	±	7.6 29.6	±	7.8 28.1	±	6.3 27.2	±	5.5 <.001	*** <.001	*** <.001	*** .007**
Blood	type,	n	(%)     <.001	*** .181 .004	** .938
O 6401	(47.0) 5595	(46.7) 242	(49.3) 564	(49.7)     
A 5069	(37.2) 4439	(37.0) 188	(38.3) 442	(39.0)     
B 1621	(11.9) 1452	(12.1) 53	(10.8) 116	(10.2)     
AB 522	(3.8) 502	(4.2) 8	(1.6) 12	(1.1)     
DCD,	n	(%)     .940 .999 .941 .974
No 10	802	(79.3) 9517	(79.4) 390	(79.4) 895	(78.9)     
Yes 2815	(20.7) 2475	(20.6) 101	(20.6) 239	(21.1)     
ECD,	n	(%)     <.001	*** <.001	*** <.001	*** <.001	***
No 7028	(51.6) 5596	(46.7) 385	(78.4) 1047	(92.3)     
Yes 6589	(48.4) 6396	(53.3) 106	(21.6) 87	(7.7)     
Diabetes	(any	type),	n	(%)     <.001	*** <.001	*** <.001	*** .008**
No 10	293	(76.4) 8816	(74.2) 420	(87.3) 1057	(94.5)     
Yes 3182	(23.6) 3060	(25.8) 61	(12.7) 61	(5.5)     
Hypertension,	n	(%)     <.001	*** <.001	*** <.001	*** <.001	***
No 5519	(41.0) 4377	(36.8) 290	(60.2) 852	(76.9)     
Yes 7957	(59.0) 7509	(63.2) 192	(39.8) 256	(23.1)     
PHS	increased	risk,	n	(%)     <.001	*** <.001	*** <.001	*** <.001	***
No 10	675	(78.4) 10	241	(85.4) 184	(37.5) 250	(22.0)     
Yes 2936	(21.6) 1745	(14.6) 307	(62.5) 884	(78.0)     
Cause	of	death,	n	(%)     <.001	*** <.001	*** <.001	*** .795
Anoxia 5231	(38.4) 4259	(35.5) 278	(56.6) 694	(61.2)     
Cerebrovascular 5850	(43.0) 5536	(46.2) 121	(24.6) 193	(17.0)     
Head	Trauma 2162	(15.9) 1868	(15.6) 78	(15.9) 216	(19.0)     
Other 374	(2.7) 329	(2.7) 14	(2.9) 31	(2.7)     
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than	50%)	 that	 showed	 a	 higher	 percentage	of	 glomerulosclerosis	
>20%	and	moderate-to-severe	interstitial	fibrosis.
3.7 | Kidney transplant center/OPO/UNOS region 
utilization of HCV viremic kidneys
Figure	4	shows	the	heat	map	geographic	data	(the	number	of	kid-
neys)	from	viremic	donors	recovered	(Figure	4A)	and	transplanted	
(Figure	 4B)	 based	 on	 the	UNOS	Regions.	 The	UNOS	Regions	 2	
and	3	were	more	 likely	 to	procure,	and	transplant	kidneys	from	
viremic	donors.	Figures	5	and	6	show	the	geographic	distribution	
of	 transplantation	with	 viremic	 kidneys	 according	 to	 the	OPOs	
and	 individual	 transplant	 centers,	 respectively.	 The	 number	 of	
OPOs	that	transplanted	at	least	25	kidneys	from	viremic	donors	
increased	 from	only	 one	 in	 2015	 to	 six	 in	 2018.	 There	were	 at	
least	two	centers	that	transplanted	more	than	60	viremic	donor	
kidneys	in	2018.
3.8 | Forecasting number of potential viremic 
kidneys by 2023
We	forecasted	a	potential	number	of	HCV	NAT+	DD	kidneys	 that	
may	 become	 available	 in	 2023,	 based	 on	 actual	 numbers	 of	 such	
kidneys	from	2015-2018,	using	time	series	trend	adjusted	exponen-
tial	 smoothing	method.	We	predict	 about	2092	HCV-positive	 kid-
neys	from	deceased	donors	would	be	available	by	2023	(Figure	7),	
the model assumes that the opioid epidemic and related overdose 
deaths	continue	to	rise	exponentially	with	the	same	trend.
4  | DISCUSSION
This	 study	 reveals	 some	 key	 insights	 about	 the	 recent	 trends	 in	
kidney	 transplant	utilization	 in	 the	United	States:	 (a)	 an	 increasing	
number	 and	 utilization	 rates	 of	 Ab+/NAT−	 kidneys	 (annual	 trans-
plant	rate	increased	from	35.9%	in	2015	to	66%	in	2018)	showing	a	
F I G U R E  2  Disposition	of	deceased	donor	kidneys	based	on	HCV	Ab	and	NAT	status	between	January	1,	2015,	and	Dec	31,	2018,	in	the	
United	States
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positive	change	in	transplant	centers'	behavior	and	patient	accept-






group	 (65.4%);	 (d)	PHS	designation	 (OR	1.20,	CI	95%	CI	1.15-1.29)	
and	HCV	status	(2.29;	95%	CI	2.15-2.43)	were	independently	asso-




glomerulosclerosis	 (GS)	 >20%	 and	 moderate-to-severe	 interstitial	
fibrosis	(IF);	(f)	the	reasons	for	high	kidney	discards	are	multifacto-
rial,	could	partially	be	explained	by	KDPI	score,	the	performance	of	





Decision	 to	 discard	 a	 deceased	 donor	 kidney	 is	 influenced	 by	












F I G U R E  3  KDPI	distribution	by	HCV	status	and	disposition	(transplant	vs.	discard)	between	January	1,	2015,	and	December	31,	2018,	in	
the	United	States	(dashed	and	solid	vertical	lines	indicate	median	KDPI	for	transplanted	and	discarded	kidneys,	respectively)












on	HCV	donors	 and	organ	 transplantation	 recently	 recommended	
that	HCV	Ab+/NAT−	donors	 (without	other	 increased	 risk	 factors)	
not	 be	 considered	 at	 increased	 risk	 of	HCV	 transmission.33	A	 sin-
gle-center	 study	 also	 demonstrated	 the	 safety	 of	 transplanting	









TA B L E  4  Characteristics	of	discarded	deceased	donor	kidneys	by	HCV	status	between	January	1,	2015,	and	December	31,	2018,	in	the	
United	States
 All groups Ab−, NAT− Ab+, NAT Ab±, NAT+ All ways
P-valuesa   
Ab−, NAT− vs Ab−, NAT− 
vs Ab±, 
NAT+Ab+, NAT− Ab±, NAT+
Disposition	reason,	
nb	(%)
    <.001	*** <.001	*** <.001	*** .079
AKI 784	(5.8) 722	(6.0) 26	(5.3) 36	(3.2)     
Anatomical	
abnormalities
772	(5.7) 723	(6.0) 23	(4.7) 26	(2.3)     
Biopsy 3943	(29.0) 3768	(31.4) 57	(11.6) 118	(10.4)     
CIT 294	(2.2) 262	(2.2) 5	(1.0) 27	(2.4)     
Diseased organ 400	(2.9) 385	(3.2) 1	(0.2) 14	(1.2)     
Donor quality 333	(2.4) 273	(2.3) 20	(4.1) 40	(3.5)     
Donor social 
history
19	(0.1) 4	(0.0) 3	(0.6) 12	(1.1)     
HCV 120	(0.9) 8(0.1) 40	(8.1) 72	(6.3)     




5536	(40.7) 4496	(37.5) 298	(60.7) 742	(65.4)     
Non-renal	cancer 102	(0.7) 101	(0.8) 7	(1.4) 1	(0.1)     
Organ trauma 
during recovery
521	(3.8) 499	(4.2) 2	(0.4) 15	(1.3)     
Pump 335	(2.5) 327	(2.7) 1	(0.2) 8	(0.7)     
Renal cancer 35	(0.3) 32	(0.3) 2	(0.4) 1	(0.1)     
Turned	down	in	
the OR
62	(0.5) 60	(0.5) 4	(0.8) 2	(0.2)     
Vascular	disease 145	(1.1) 141	(1.2) NA	(NA) 3	(0.3)     
Warm ischemia 
time
66	(0.5) 62	(0.5) NA	(NA) 2	(0.2)     

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































recipients	 is	more	beneficial	 than	 for	HCV	Ab	or	NAT−	 recipients,	
in	terms	of	graft	or	patient	survival	and	cost-effectiveness,	remains	
to	be	seen.	Education	of	public	and	private	payers	is	crucial	to	help	
provide	payment	 for	 initial	HCV	treatment	and	additional	 therapy,	
should	 resistance	 be	 a	 challenge	 post-transplant	 (<5%);	 thus,	 we	






into	 negative	 recipients	 could	 be	 cost-effective	 with	 an	 incremen-







F I G U R E  4  Geographic	distribution	by	the	UNOS	Region	for	hepatitis	C	virus	(HCV)	infected	donors	and	transplants	with	HCV-infected	
kidneys
F I G U R E  5  Geographic	distribution	of	hepatitis	C	virus	(HCV)	infected	(NAT+)	kidney	transplantation	by	the	organ	procurement	
organization	(OPO)	donation	service	area	(DSA)	between	2015	and	2018
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Unfortunately,	 during	 the	 study	 period,	 the	 discards	 for	 HCV	








rience on this evolving topic.
Another	issue	with	HCV	viremic	donors	is	that	they	are	unlikely	
to	be	placed	 in	 younger	 recipients	 (longevity	matched	donor-re-
cipient	pairs,	mainly	 allocation	of	KDPI	<	20%	kidneys	 to	 young	
recipients	 with	 the	 longest	 post-transplant	 survival	 expectancy)	
due	to	adverse	impact	of	HCV	Ab	positivity	on	KDPI	calculation,	
F I G U R E  6  Geographic	distribution	of	hepatitis	C	virus	(HCV)	infected	(NAT+)	kidney	transplantation	by	transplant	center	between	2015	
and	2018
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calculations	 and	 recommend	 uniform	 utilization	 of	 NAT	 status	
alone.39-41
Strengths	of	our	study	include	a	large	sample	size	of	a	national	
data	 set.	 Limitations	 of	 our	 study	 include	 the	 following:	 (a)	 it	 is	 a	
retrospective	registry	data	analysis	without	a	control	group;	(b)	the	
OPTN	data	set	does	not	include	information	regarding	potential	do-
nors in whom a donor consent was not obtained and not recovered 
for	transplant;	(c)	missing	data	can	introduce	bias;	(d)	reporting	de-
lays and labeling errors might happen.
In	conclusion,	HCV-positive	donors	are	likely	to	increase	in	near	
future	years,	unless	there	is	a	dramatic	reduction	in	the	current	opi-
oid	 crisis.	Organs	 from	HCV-positive	 donors	 could	 potentially	 ex-
pand	the	organ	pool,	especially	given	the	effective	antiviral	therapy	
available	against	HCV,	and	 increase	access	 to	 transplant	across	all	
patients,	including	HCV-negative	recipients.	PHS	labeling	effect	on	
discard	requires	rediscussion	of	purpose	and	utility	of	classification.	
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